SECTION 1

Cancer patients' lived experiences on their pathway to CAR-T cell trial participation

To gain a deeper understanding of journeys before, during, and after CAR-T therapy for hematological malignancy, we gathered insights and feedback from patients, caregivers and healthcare professionals (HCPs).

Download the executive summary of the full report